The results of the OPTION-DM trial showed that all three treatment pathways had equal pain control, in terms of both statistical and clinical significance. The P-A pathway led to fewer monotherapy discontinuations due to treatment-emergent AEs and was also most preferred by participants at the end of the trial, suggesting that this may be the safest choice as a first line of therapy. Importantly, although the trial was not primarily designed to examine the benefit of combination treatment when there is suboptimal response to a monotherapy, this pragmatic trial demonstrated that combination treatment, where needed, was well tolerated and can lead to further reduction in pain following the introduction of second-line therapy.
Optimal pharmacotherapy pathway in adults with diabetic peripheral neuropathic pain: the OPTION-DM RCT · Conclusions
Conclusions
Attribution. Solomon Tesfaye; Gordon Sloan; Jennifer Petrie; David White; Mike Bradburn; Tracey Young et al. (2022). Optimal pharmacotherapy pathway in adults with diabetic peripheral neuropathic pain: the OPTION-DM RCT. National Institute for Health and Care Research. Copyright © 2022 Tesfaye et al. This work was produced by Tesfaye et al. under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use, distribution, reproduction and adaption in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/. For attribution the title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited. Licensed under CC BY 4.0. NCBI Bookshelf NBK585245. CC BY 4.0. Original source ↗. Text reproduced from the Bookshelf XML without changing wording; figures, images and supplements are not reproduced.